New hope for rare blood disorder: trial tests targeted combo therapy
NCT ID NCT07335887
Summary
This study is testing a new combination of drugs for adults with a rare and serious blood disorder called AL amyloidosis, specifically those with a genetic marker called t(11;14). The goal is to see if adding a new drug called sonrotoclax to standard treatments can better control the disease and improve the function of affected organs like the heart and kidneys. Researchers will measure how well the treatment works and monitor its safety over 12 treatment cycles.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS (AL) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.